BofA raised the firm’s price target on CVS Health (CVS) to $89 from $85 and keeps a Buy rating on the shares. Stating that CVS reported “strong” Q2 results, the firm argues that the biggest takeaway from the quarter is that CVS’ strong performance in the Pharmacy & Consumer Wellness segment is a sustainable near-term tailwind. The firm sees a sustained path to positive earnings revisions as Aetna margins continue to improve and retail pharmacy performance continues to “exceed a very low bar,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health: Strong Market Position and Financial Performance Drive Buy Rating
- CVS Health price target raised to $80 from $79 at Barclays
- CVS Health Reports Strong Q2 Revenue Growth Amid Challenges
- Unusually active option classes on open July 31st
- Morning Movers: Roblox skyrockets following second quarter results